ProCE Banner Activity

CME

Adopting New Approaches in AL Amyloidosis: Expert Perspectives on Latest Evidence

Multimedia
In this on-demand webcast of a live webinar, expert faculty review the latest safety and efficacy data supporting current management of newly diagnosed and relapsed light-chain amyloidosis.

Physicians: Maximum of 1.50 AMA PRA Category 1 Credits

Released: February 11, 2022

Expiration: February 10, 2023

No longer available for credit.

Share

Faculty

Ankit Kansagra

Ankit Kansagra, MD

Eugene P. Frenkel MD Scholar of Clinical Medicine
Assistant Professor of Medicine
Division of Hematology/Oncology
University Texas Southwestern Medical Center
Dallas, Texas

Shaji K. Kumar

Shaji K. Kumar, MD

Mark and Judy Mullins Professor of Hematological Malignancies
Chair, Myeloma Amyloidosis Dysproteinemia Group
Consultant, Division of Hematology
Mayo Clinic
Rochester, Minnesota

Vaishali Sanchorawala

Vaishali Sanchorawala, MD

Professor of Medicine
Director, Amyloidosis Center
Boston University School of Medicine
Director, Autologous Stem Cell Transplantation Program
Section of Hematology-Oncology
Boston Medical Center
Boston, Massachusetts

Provided by

Provided by Clinical Care Options, LLC
ProCE Banner

Supporters

Supported by an educational grant from

Janssen administered by Scientific Affairs

Target Audience

This program is intended for physicians and other healthcare professionals who care for patients with AL amyloidosis.

Learning Objectives

Upon completion of this activity, participants should be able to:
  • Recognize and diagnose AL amyloidosis through timely and accurate typing of the precursor protein to guide specific management approaches
  • Integrate into practice up-to-date efficacy and safety data on currently available and novel regimens to treat newly diagnosed and relapsed/refractory AL amyloidosis based on accurate risk and response assessment
  • Based on the current best evidence, implement supportive therapy in AL amyloidosis to improve quality of life, relieving symptom, and sustain organ function
  • Appraise ongoing clinical trials evaluating novel therapy for the treatment of patients with AL amyloidosis

Disclosure

Clinical Care Options, LLC (CCO) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose all financial conflicts of interest (COI) they may have with ineligible companies. All relevant COI are thoroughly vetted and mitigated according to CCO policy. CCO is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.

The faculty reported the following relevant financial relationships or relationships to products or devices they have with ineligible companies related to the content of this educational activity:

Faculty Disclosure

Primary Author

Ankit Kansagra, MD

Eugene P. Frenkel MD Scholar of Clinical Medicine
Assistant Professor of Medicine
Division of Hematology/Oncology
University Texas Southwestern Medical Center
Dallas, Texas

Ankit Kansagra, MD, has disclosed that he has received funds for research support from AbbVie, Bristol-Myers Squibb/Celgene, GlaxoSmithKline, and Janssen and consulting fees from AbbVie, Alnylam, Bristol-Myers Squibb/Celgene, GlaxoSmithKline, Janssen, Oncopeptides, and Takeda.

Shaji K. Kumar, MD

Mark and Judy Mullins Professor of Hematological Malignancies
Chair, Myeloma Amyloidosis Dysproteinemia Group
Consultant, Division of Hematology
Mayo Clinic
Rochester, Minnesota

Shaji K. Kumar, MD, has disclosed that he has received funds for research support from AbbVie, Bristol-Myers Squibb, Celgene, Genentech, Janssen, MedImmune, Oncopeptides, Takeda, and TeneoBio and consulting fees from AbbVie, Bristol-Myers Squibb, Celgene, Genentech, Janssen, Oncopeptides, and Takeda.

Vaishali Sanchorawala, MD

Professor of Medicine
Director, Amyloidosis Center
Boston University School of Medicine
Director, Autologous Stem Cell Transplantation Program
Section of Hematology-Oncology
Boston Medical Center
Boston, Massachusetts

Vaishali Sanchorawala, MD, has disclosed that she has received funds for research support from Caelum, Celgene, Janssen, Karyopharm, Oncopeptide, Prothena, Sorento, and Takeda and consulting fees from Caelum, Janssen, Prothena, and Pfizer.

Staff Disclosure

Staff

Gordon Kelley,

Clinical Editor
Clinical Care Options, LLC

Gordon Kelley has no relevant conflicts of interest to report.

Lisa Kuhns, PhD

Lisa Kuhns, PhD, has disclosed that she has received other financial or material support from Alcresta Therapeutics, Primus, Parnell, BioMerieux, and Beckman Coulter.

Jim Mortimer,

Product Director, Hematology/Oncology
Clinical Care Options, LLC

Jim Mortimer has no relevant conflicts of interest to report.

Kevin Obholz, PhD

Editorial Director, Hematology/Oncology

Kevin Obholz, PhD, has no relevant conflicts of interest to report.

Shara Pantry, PhD

Associate Scientific Director

Shara Pantry, PhD, has no relevant conflicts of interest to report.

Timothy A. Quill, PhD

Senior Managing Editor

Timothy A. Quill, PhD, has no relevant conflicts of interest to report.

Instructions for Credit

Accreditation

Joint Accreditation Statement

In support of improving patient care, Clinical Care Options, LLC (CCO) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physician Continuing Medical Education

Credit Designation

CCO designates this enduring material for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Additional Information

Participation in this self-study activity should be completed in approximately 1.5 hours. To successfully complete this activity and receive credit, participants must follow these steps during the period from February 11, 2022, through February 10, 2023:

1. Register online at http://www.clinicaloptions.com.
2. Read the target audience, learning objectives, and faculty disclosures.
3. Study the educational activity online or printed out.
4. Submit answers to the posttest questions and evaluation questions online.

You must receive a test score of at least 65% and respond to all evaluation questions to receive a certificate. After submitting the evaluation, you may access your online certificate by selecting the certificate link on the posttest confirmation page. Records of all CME/CE activities completed can be found on the "CME/CE Manager" page. There are no costs/fees for this activity.

Program Medium

This program has been made available online.


Goal


The goal of this activity is to improve the knowledge, competence, and performance of physicians and other healthcare professionals to confidently and competently integrate currently available and novel regimens to treat newly diagnosed and relapsed/refractory AL amyloidosis into their clinical practices.